<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36790806</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of Post-COVID-19 Condition Symptoms and Employment Status.</ArticleTitle><Pagination><StartPage>e2256152</StartPage><MedlinePgn>e2256152</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2256152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.56152</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Little is known about the functional correlates of post-COVID-19 condition (PCC), also known as long COVID, particularly the relevance of neurocognitive symptoms.</AbstractText><AbstractText Label="OBJECTIVE">To characterize prevalence of unemployment among individuals who did, or did not, develop PCC after acute infection.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This survey study used data from 8 waves of a 50-state US nonprobability internet population-based survey of respondents aged 18 to 69 years conducted between February 2021 and July 2022.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were self-reported current employment status and the presence of PCC, defined as report of continued symptoms at least 2 months beyond initial month of symptoms confirmed by a positive COVID-19 test.</AbstractText><AbstractText Label="RESULTS">The cohort included 15&#x202f;308 survey respondents with test-confirmed COVID-19 at least 2 months prior, of whom 2236 (14.6%) reported PCC symptoms, including 1027 of 2236 (45.9%) reporting either brain fog or impaired memory. The mean (SD) age was 38.8 (13.5) years; 9679 respondents (63.2%) identified as women and 10&#x202f;720 (70.0%) were White. Overall, 1418 of 15&#x202f;308 respondents (9.3%) reported being unemployed, including 276 of 2236 (12.3%) of those with PCC and 1142 of 13&#x202f;071 (8.7%) of those without PCC; 8229 respondents (53.8%) worked full-time, including 1017 (45.5%) of those with PCC and 7212 (55.2%) without PCC. In survey-weighted regression models excluding retired respondents, the presence of PCC was associated with a lower likelihood of working full-time (odds ratio [OR], 0.71 [95% CI, 0.63-0.80]; adjusted OR, 0.84 [95% CI, 0.74-0.96]) and with a higher likelihood of being unemployed (OR, 1.45 [95% CI, 1.22-1.73]; adjusted OR, 1.23 [95% CI, 1.02-1.48]). The presence of any cognitive symptom was associated with lower likelihood of working full time (OR, 0.70 [95% CI, 0.56-0.88]; adjusted OR, 0.75 [95% CI, 0.59-0.84]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">PCC was associated with a greater likelihood of unemployment and lesser likelihood of working full time in adjusted models. The presence of cognitive symptoms was associated with diminished likelihood of working full time. These results underscore the importance of developing strategies to treat and manage PCC symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunz Trujillo</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safarpour</LastName><ForeName>Alauna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santillana</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ognyanova</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rutgers University, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druckman</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Northwestern University, Evanston, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 MH132335</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2023.0157</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014478" MajorTopicYN="N">Unemployment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Perlis reported receiving personal fees from Burrage Capital, Genomind, Psy Therapeutics, Circular Genomics, and Takeda outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36790806</ArticleId><ArticleId IdType="pmc">PMC9932847</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.56152</ArticleId><ArticleId IdType="pii">2801458</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October. 2021. Accessed June 21, 2022. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. . Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years&#x2014;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713-717. doi:10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Chappuis F, Guessous I; CoviCare Study Team . The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization. Sci Rep. 2022;12(1):14505. doi:10.1038/s41598-022-18673-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18673-z</ArticleId><ArticleId IdType="pmc">PMC9403954</ArticleId><ArticleId IdType="pubmed">36008436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatys-Bogacka Z, Mazurkiewicz I, Slowik J, et al. . Brain fog and quality of life at work in non-hospitalized patients after COVID-19. Int J Environ Res Public Health. 2022;19(19):12816. doi:10.3390/ijerph191912816</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912816</ArticleId><ArticleId IdType="pmc">PMC9564568</ArticleId><ArticleId IdType="pubmed">36232113</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, et al. . Brain imaging before and after COVID-19 in UK Biobank. medRxiv. Preprint posted online August 18, 2021. doi:10.1101/2021.06.11.21258690</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.11.21258690</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford J, Green J, Quintana A, et al. . Evaluating the generalizability of the COVID States survey&#x2014;a large-scale, non-probability survey. OSF Preprints. Preprint posted online March 7, 2022. doi:10.31219/osf.io/cwkg7</Citation><ArticleIdList><ArticleId IdType="doi">10.31219/osf.io/cwkg7</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>